Molecular structure of Furosemide, CAS Number: 54-31-9
Furosemide (CAS 54-31-9)
Alternate Names:
Frusemide; Lasix; Furanthril; Errolon; Fusid; Fuluvamide; Furanthryl; Furantril; Furosemid
Application:
Furosemide is an inhibitor of NKCC and a GABAA receptor antagonist
CAS Number:
54-31-9
Purity:
≥99%
Molecular Weight:
330.74
Molecular Formula:
C12H11ClN2O5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Furosemide is a diuretic compound that functions by inhibiting the reabsorption of sodium and chloride in the ascending loop of Henle in the kidneys. This inhibition leads to increased excretion of water, sodium, chloride, and other electrolytes. Furosemide achieves this by blocking the Na+/K+/2Cl- symporter, which is responsible for transporting these ions across the cell membrane. Furosemide′s mechanism of action involves its binding to the chloride-binding site of the transporter, preventing the movement of ions across the membrane. As a result, furosemide effectively promotes diuresis by altering the ion transport processes in the kidney, without affecting the reabsorption of water in other parts of the nephron.
Furosemide (CAS 54-31-9) References
- The efficiency concept in pharmacodynamics. | Alván, G., et al. 1999. Clin Pharmacokinet. 36: 375-89. PMID: 10384860
- Application of the carbonic anhydrase inhibitory effect of furosemide to the study of furosemide release from two of its diuretic derivatives. | Navon, G., et al. 1975. J Med Chem. 18: 1152-4. PMID: 1177262
- [Activation of the fibrinolytic system by furosemide (author's transl)]. | Bruhn, HD., et al. 1975. Med Klin. 70: 1125-7. PMID: 1223615
- [Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?]. | Spannheimer, A., et al. 2002. Praxis (Bern 1994). 91: 1467-75. PMID: 12360682
- Effects of oxygen plasma treatment on the surface wettability and dissolution of furosemide compacts. | Naseem, A., et al. 2003. J Pharm Pharmacol. 55: 1473-8. PMID: 14713357
- The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. | Cleland, JG., et al. 1988. Eur Heart J. 9: 132-41. PMID: 2832173
- Pharmacodynamics of intravenous frusemide bolus in critically ill patients. | Huang, A., et al. 2017. Crit Care Resusc. 19: 142-149. PMID: 28651510
- Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. | Heinemeyer, G. 1987. Clin Pharmacokinet. 13: 1-25. PMID: 3304768
- [An unusual case: hemorrhagic bullous pemphigoid following furosemide treatment]. | Ingber, A., et al. 1986. Z Hautkr. 61: 1554-6. PMID: 3544545
- Intravenously administered frusemide increases glomerular permeability. | Ala-Houhala, I., et al. 1987. Clin Sci (Lond). 73: 365-70. PMID: 3665358
- Frusemide in heart failure of infancy. | Richardson, H. 1971. Arch Dis Child. 46: 520-4. PMID: 5565464
- [Effect of furosemide on venous capacity in anuric or binephrectomized patients]. | Kohn, P. and Kroiss, A. 1977. Acta Med Austriaca. 4: 190-3. PMID: 613699
- [Pharmacokinetics and electrolyte balance following administration of furosemide in pregnant women with E gestosis]. | Peiker, G., et al. 1984. Pharmazie. 39: 336-9. PMID: 6473496
- Interaction between frusemide and aspirin. | Oyekan, AO., et al. 1984. Gen Pharmacol. 15: 163-6. PMID: 6714643
- [Pharmacokinetic interference between furosemide and cephalosporins]. | Iakovlev, VP., et al. 1981. Antibiotiki. 26: 287-90. PMID: 7235669
Inhibitor of:
δENaC, AE3, AQP1, AQP12, AQP12A, AQP12B, AQP2, AQP3, AQP4, AQP6, ATAD4, BC048943, BOCT, C20orf111, C4ST-2, C8orf5, CA III, CA IV, CHMP4A, claudin-2, CLC-3, CLC-4, CLC-6, CLC-K1, CLCA3_Clac3, CLIC5, cyclin M3, DFNB59, FXYD7, GABA Receptor, GABAA R rho 1, GABAA Rβ2, GABAA Rδ, GABAA Rε, GABAA Rγ2, GABAA Rρ3, GABAA Rp, GABAC Rρ3, Glut9, Glycophorin A, GPR89, KCC1, KCC2a, KCC2b, KCC3, KCC4, LHFPL5, LRRC8D, MFSD6L, MFSD9, Mmgt2, MRS2L, Na+ CP type XIα, NCBE, NHEDC2, NKAIN1, NKCC, NKCC1, NKHC1, NPT1, OAT, OAT1, OAT2, OAT3, OAT6, Oatp3, Olfr509, Olfr666, Olfr667, Olr1499, Olr1514, Olr1646, Olr208, Olr213, Olr245, Olr34, Olr395, Olr419, OPG, OSR1, PIPES, Prestin, RDS, Relaxin 1, RENBP, RFC-1, RhAG, SLC12A8, SLC12A9, SLC17A (solute carrier family 17), SLC17A2, SLC17A4, SLC22A11, SLC22A14, SLC22A23, SLC22A29, SLC22A9, SLC26A11, SLC26A6, SLC41A1, spectrin, spectrin αII, Stereocilin, SVCT3, TMC2, TMEM14A, TMEM63B, TMIE, UST1R, WNK1, and WNK3.Activator of:
AGTRAP, AQP12A, Barttin, CA I, CA VB, CA XIV, cyclin M1, GABA T-1, Histamine, MFSD5, MKP-4, Na+ CP type IIIβ, NaDC-3, NHE-9, OCTN2, ORMDL2, Otoconin 90, Renin, Renin-1, Sfta2, SLC10A5, SLC22A12, SLC26A7, SLC26A8, SLC35E4, SLC41A3, SLC45A4, SLC46A3, Sodium Chloride, TMC1, TTYH1, and V-ATPase G1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Furosemide, 50 mg | sc-203961 | 50 mg | $41.00 |